Lilly puts another $3 billion into the Wisconsin plant it had just bought

Eli Lilly said on Dec. 5, 2024, that it will spend another $3 billion to expand a manufacturing plant in Kenosha County, Wisconsin, bringing its total planned investment at the site to about $4 billion ^[2][3]. The company said it will add 750 jobs to a facility that currently employs more than 100 people ^[1][2][3].

Lilly bought the plant earlier this year from Nexus Pharmaceuticals ^[2]. With this new spending, the company called it "our single largest U.S. manufacturing investment outside our home state of Indiana" ^[1][2][3]. The expanded site will make injectable medicines, assemble devices, and handle packaging for drugs across several disease areas, including diabetes and obesity ^[3]. Construction on the expansion is set to start next year, and Lilly has said it expects production at the facility to begin at the end of 2025 ^[2].

The investment is aimed at boosting supply of tirzepatide, the active ingredient in Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro ^[1][2]. Both drugs were in shortage in the U.S. for much of 2024 ^[2]. The FDA removed tirzepatide from its shortage list earlier in the year but was reconsidering that decision after a lawsuit from a group representing compounding pharmacies that make unapproved versions of the drug ^[2]. More than 5.2 million prescriptions had been written for Zepbound since it launched in late 2023, according to IQVIA data cited by an analyst ^[2].

Lilly said it has now committed more than $23 billion since 2020 to building, expanding, and acquiring manufacturing sites worldwide ^[2][3]. The new jobs at the Wisconsin plant will include operators, technicians, engineers, and scientists, and the expansion is expected to support more than 2,000 construction jobs during the building phase ^[3]. Rival Novo Nordisk, which makes Wegovy, has also spent billions on manufacturing, including an $11 billion deal earlier in 2024 to take over three sites from contract manufacturer Catalent ^[2].

Why it matters for patients

Shortages of tirzepatide products have made it hard for some patients to get prescriptions filled at their local pharmacy, and have pushed some people toward compounded versions of the drug that are not FDA-approved ^[2]. More factory capacity is meant to help close that gap over time, but the sources do not say when patients might notice shorter waits or easier refills, since the expanded Wisconsin site is not expected to start producing medicine until the end of 2025 at the earliest ^[2].

The investment does not address drug pricing directly. None of the sources mention list prices, insurance coverage, or out-of-pocket costs for Zepbound or Mounjaro. Patients weighing these drugs should know that manufacturing expansion is a supply-side fix, not a guarantee of lower costs or immediate availability.

The ongoing legal fight over compounded tirzepatide is also relevant. The FDA had removed tirzepatide from its shortage list, which under federal rules limits when compounding pharmacies can legally make copies of the drug, but the agency was reconsidering that call after a lawsuit from a compounding industry group ^[2]. That means the legal status of compounded tirzepatide products was still unsettled at the time of this announcement.

What happens next

Lilly said construction on the Wisconsin expansion would begin in 2025, with production at the facility expected to start by the end of that year ^[2]. The sources do not specify a date for when the FDA will resolve the shortage-list dispute over compounded tirzepatide.